However, typical dosage forms of the invention comprise a pharmaceutically acceptable salt and co-crystal of cis-itraconazole, posaconazole or saperconazole or its stereoisomers, selected from the group consisting of cis-itraconazole, posaconazole or saperconazole malic acid co-crystal and cis-itraconazole, posaconazole or saperconazole-HCl, and pharmaceutically acceptable hydrates, solvates, poly